Composition for collecting placental stem cells and methods of using the composition

Patent metadata

Field	Value
Publication number	US-9598669-B2
Application number	US-64881206-A
Country	US
Kind code	B2
Filing date	Dec 28, 2006
Priority date	Dec 29, 2005
Publication date	Mar 21, 2017
Grant date	Mar 21, 2017

Abstract

The present invention provides improved compositions and methods for the collection of stem cells from an organ, e.g., placenta. The invention provides a stem cell collection composition comprising an apoptosis inhibitor and, optionally, an enzyme such as a protease or mucolytic enzyme, vasodilator, necrosis inhibitor, oxygen-carrying perfluorocarbon, or an organ preserving compound. The invention provides methods of using the stem cell collection composition to collect stem cells and to preserve populations of stem cells.

First claim

What is claimed is:

1. A composition comprising, in a physiologically-acceptable solution, a JNK inhibitor, wherein said JNK inhibitor is 3-(4-fluoro-phenyl)-1H-indazole-5-carboxylic acid amide; a protease; an oxygen-carrying perfluorocarbon; 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione; atrial natriuretic peptide (ANP); and either pyrrolidine dithiocarbamate or clonazepam;
wherein said composition is not a naturally-occurring composition, and wherein said JNK inhibitor is an inhibitor of apoptosis; and
wherein the composition is suitable for collecting placental stem cells.

2. The composition of claim 1 , wherein said protease is present in an amount sufficient to detectably dissociate cells of a tissue comprising stem cells.

3. The composition of claim 1 wherein said physiologically-acceptable solution is a saline solution or culture medium.

4. The composition of claim 3 wherein said saline solution is 0.9% NaCl solution or phosphate buffered saline.

5. The composition of claim 1 , wherein said protease is a matrix metalloprotease or a neutral protease.

6. The composition of claim 5 , wherein said matrix metalloprotease is collagenase.

7. The composition of claim 5 , wherein said neutral protease is thermolysin or dispase.

8. The composition of claim 1 , wherein said composition comprises hyaluronidase.

9. The composition of claim 1 , additionally comprising hydroxyethyl starch, lactobionic acid and raffinose.

10. The composition of claim 1 , additionally comprising UW solution.

11. The composition of claim 1 , wherein said JNK inhibitor is an indazole.

12. The composition of claim 1 comprising a plurality of stem cells.

13. The composition of claim 12 , wherein said stem cells comprise CD34 + stem cells.

14. The composition of claim 13 , wherein said CD34 + stem cells comprise CD34 + CD38 − stem cells.

15. The composition of claim 13 , wherein said CD34 + CD38 − stem cells are part of a population of CD34 + CD38 − stem cells present in placental perfusate as a higher percentage of total nucleated cells as compared to the percentage of CD34 + CD38 − cells in cord blood.

16. The composition of claim 12 , wherein said stem cells are CD34 − stem cells.

17. The composition of claim 16 , wherein said CD34 − stem cells are additionally HLA-G + or CD200 + .

18. The composition of claim 16 , wherein said CD34 − stem cells are additionally OCT-4 + , CD73 + , or CD105+.

Assignees

• Edinger James W
• Heidaran Mohammad
• Hofgartner Wolfgang
• Anthrogenesis Corp

Inventors

• Edinger James W
• Heidaran Mohammad
• Hofgartner Wolfgang

Classifications

• C12N2501/48

  Regulators of apoptosis · CPC title

• C12N5/0605 Primary

  Cells from extra-embryonic tissues, e.g. placenta, amnion, yolk sac, Wharton's jelly · CPC title

• C12N2501/999

  Small molecules not provided for elsewhere · CPC title

• C12N5/00

  Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor; (plant reproduction by tissue culture techniques A01H4/00) · CPC title

• C12N5/0607 Primary

  Non-embryonic pluripotent stem cells, e.g. MASC (induced pluripotent stem cells C12N5/0696) · CPC title